帕潘立酮棕榈酸酯
帕利哌酮
抗精神病药
子群分析
医学
心理学
精神分裂症(面向对象编程)
药理学
内科学
精神科
荟萃分析
作者
Tianmei Si,Jian-xiong Fan,X. Wang,C. Wang,Cheng Xu,Jianmin Zhuo,Yi Feng
出处
期刊:Pharmacopsychiatry
[Georg Thieme Verlag KG]
日期:2015-12-17
卷期号:49 (01): 32-41
被引量:3
标识
DOI:10.1055/s-0035-1565133
摘要
Safely tapering current antipsychotic medication, while balancing efficacy and tolerability, is an important consideration when switching patients from their antipsychotic therapy to a new treatment. The efficacy and tolerability of paliperidone palmitate one-month (PP1M) in Chinese patients switched from previous antipsychotic treatments were examined in order to develop effective switching and dosing strategies.A 13-week open-label, single arm, prospective, interventional study was conducted in Chinese patients (n = 610) with acute schizophrenia to examine their response, by previous treatment group, when switched to PP1M (75-150 mg eq).Among 610 patients with ≥ 30% reduction in PANSS total score were 191/263 (72.6%) risperidone/paliperidone extended-release patients, 36/52 (69.2%) olanzapine patients, and 214/293 (73.0%) other antipsychotic patients. Patient functioning and adherence were significantly (p ≤ 0.05) improved for all subgroups.Patients on higher doses of prior antipsychotics generally took longer to withdraw from their current medication. Most patients were administered the 100 mg eq dose, and all subgroups received a similar mean dose (114-119 mg eq) of PP1M. Recommendations for transitioning patients to PP1M from each subgroup are discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI